Today we're featuring a case study on how BioAgilytix developed a cell-based assay to determine the prevalence of pre-existing antibodies against the AAV9 serotype in patients for a gene therapy clinical trial.
We find it critical to stay on top of the latest industry developments to inform our own work and help our customers best address emerging bioanalytical challenges and opportunities; we've compiled some of our favorite recent industry articles of interest to share with you.
In this Q&A session we talk to David Rusnak, one of the first 3 employees to join BioAgilytix when it was founded 10 years ago and currently our Director of Laboratory Systems and Automation, to learn more about his experience growing with the organization from its very start – and what still keeps him excited to come to work each day.
Platforms
Services